<DOC>
	<DOCNO>NCT01354457</DOCNO>
	<brief_summary>The purpose study determine whether fractionate RIT Epratuzumab radiolabeled Epratuzumab effective treatment relapse refractory ALL .</brief_summary>
	<brief_title>Safety Efficacy Radio-immunotherapy ( RIT ) Patients With Relapse Refractory Acute Lymphoblastic Leukaemia ( ALL ) B CD22+</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Age 1870 year BALL ( OMS ) &gt; =20 % blast bone marrow CD22+ expression &gt; =70 % blast population All previously treat ALL patient experience relapse treatment failure At least 15 day since previous treatment Performance status 0 2 Creatinine clearance &gt; = 50 ml/min ( Cockroft formula ) . Serum bilirubin &lt; = 30 mmol/l Written inform consent TALL Meningeal involvement CD22 expression tumor cell &lt; 70 % HIV positive Active Hepatitis B C Active infection within 7 day start treatment Left ventricular ejection fraction &lt; 50 % . Contraindication 90YDOTAhLL2 Previous concurrent second malignancy except adequately treat basal cell carcinoma skin , curatively treat situ carcinoma cervix , curatively treat solid cancer , evidence disease least 5 year Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule Participation time another study investigational drug use Absence write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Patient relapse refractory CD22+B-acute lymphoblastic leukemia ( ALL )</keyword>
</DOC>